Professor Kappos was the Principal Investigator for the EXPAND study. The study showed oral siponimod is the first potential therapy to meaningfully delay disability profession in typical secondary progressive multiple sclerosis (MS) patients.
TrialSite News is the only digital media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe. Based in the Silicon Slopes in downtown Salt Lake City, Utah, we are founded by a team of experts in the clinical trials industry and dedicated to transparency, quality and clinical trial innovation.
159 West Broadway Suite 200
Salt Lake City, UT 84101